News

Find News

Filter articles

Applied Filters

Showing 31 to 40 of 888 results

Canada authorises compulsory licences for COVID-19 shortfalls

Canada27-03-2020Rory O'Neill

Canada is the latest country to adopt emergency measures in order to secure drugs and medical equipment in the fight against COVID-19.

Israel imports patented antivirals for treating COVID-19

Asia, Israel24-03-2020Rory O'Neill

Israel has approved generic versions of an HIV antiviral owned by AbbVie for use in treating coronavirus, despite the company still holding patent protection and doubts over its effectiveness.

FDA, FTC send message to biologics makers at competition workshop

US10-03-2020Rory O'Neill

US drug and antitrust regulators have signalled their intent to crack down on anti-competitive behaviour in the biologics and biosimilar industries, in an effort to bring down prices.

Par avoids pay-for-delay suit after court accepts payment was ‘fair’

US10-03-2020Sarah Morgan

A Virginia judge has approved Par Pharmaceutical’s settlement with a group of direct purchasers, allowing the pharmaceutical company to escape a pay-for-delay lawsuit.

Gilead to face HIV antitrust claims

US05-03-2020Rory O'Neill

Drugmakers including Gilead Sciences must face antitrust claims related to HIV drugs, after the US District Court for the District of Florida on Monday, March 3 refused to fully throw out a class-action suit implicating the company.

India restricts drug exports, fueling shortage fears

India04-03-2020Rory O'Neill

India has imposed export restrictions on drugs and active pharmaceutical ingredients (APIs), including paracetamol, amid fears over COVID-19-related shortages.

California pay-for-delay ban upheld during appeal, rules Ninth Circuit

US25-02-2020Rory O'Neill

The US Court of Appeals for the Ninth Circuit has blocked generics makers’ request to halt California’s ban on pay-for-delay deals while they challenge the legislation.

Ex-Sandoz exec pleads guilty to price fixing in generics probe

US18-02-2020Edward Pearcey

Hector Armando Kellum, a former senior executive at Novartis division Sandoz, has pleaded guilty to his role in a conspiracy to fix prices for generic drugs, the US Department of Justice announced.

Antitrust regulators to increase scrutiny of biosimilar deals

US04-02-2020Rory O'Neill

US competition regulators will increase scrutiny of biologic and biosimilar-related patent settlements, as they look to crack down on antitrust violations.

Novartis tries to block generic versions of Gilenya, enforces new patent

US30-01-2020Edward Pearcey

Swiss pharmaceutical giant Novartis is trying to stop an array of drugmakers manufacturing and selling generic versions of its newly-patented multiple sclerosis treatment, Gilenya.

Showing 31 to 40 of 888 results

LSIPR